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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 86, Revision 1 
(FGE.86Rev1): 
Consideration of aliphatic and aromatic amines and amides evaluated by 
JECFA (65th meeting)1 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and 
Processing Aids (CEF)2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY  
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (the Panel) to provide scientific advice to the Commission on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was requested to consider the Joint FAO/WHO Expert 
Committee on Food Additives (the JECFA) evaluations of flavouring substances assessed since 2000, 
and to decide whether no further evaluation is necessary, as laid down in Commission Regulation (EC) 
No 1565/2000. These flavouring substances are listed in the Register, which was adopted by 
Commission Decision 1999/217/EC and its consecutive amendments. 
The present consideration concerns 34 aliphatic and aromatic amines and amides evaluated by the 
JECFA (65th meeting). The Panel concluded that no corresponding FGE is available. 
Further two substances were evaluated by the JECFA in this group, but these are not in the Register 
(1-amino-2-propanol and acetamide; JECFA-no: 1591 and 1592, respectively). A third substance 
evaluated by the JECFA is an alpha,beta-unsaturated ketone [FL-no: 14.168] considered with respect 
to genotoxicity in FGE.223, corresponding to subgroup 5.1 of FGE.19, for which a final conclusion 
regarding its genotoxic properties could not be reached and additional data were requested. This 
consideration therefore only deals with 34 flavouring substances. 
                                                     
 
1  On request from the Commission, Question No EFSA-Q-2010-01261, adopted on 25 November 2010. 
2  Panel members: Arturo Anadon, Mona-Lise Binderup, Wilfried Bursch, Laurence Castle, Riccardo Crebelli, Karl-Heinz 
Engel, Roland Franz, Nathalie Gontard, Thomas Haertle, Trine Husøy, Klaus-Dieter Jany, Catherine Leclercq, Jean 
Claude Lhuguenot, Wim Mennes, Maria Rosaria Milana, Karla Pfaff, Kettil Svensson, Fidel Toldra, Rosemary Waring, 
Detlef Wölfle. CEF-unit@efsa.europa.eu  
3  Acknowledgement: The Panel wishes to thank the members of the Working Groups on Flavourings for the preparation of 
this Opinion: Ulla Beckman Sundh, Vibe Beltoft, Wilfried Bursch, Angelo Carere, Karl-Heinz Engel, Henrik Frandsen, 
Rainer Gürtler, Frances Hill, Trine Husøy, John Christian Larsen, Pia Lund, Wim Mennes, Gerard Mulder, Karin Nørby, 
Gerard Pascal, Iona Pratt, Gerrit Speijers, Harriet Wallin and EFSA’s staff member Kim Rygaard Nielsen for the 
preparatory work on this scientific Opinion. 
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The Panel agreed with the application of the Procedure as performed by the JECFA for 27 of the 34 
substances. The JECFA concluded on five substances [FL-no: 11.014, 14.003, 16.091, 16.093 and 
16.094] at step B4, but the Panel did not agree that appropriate studies are available for deriving 
NOAELs and accordingly the Panel in FGE.86 concluded that additional toxicity data are required for 
these five substances.  
The flavouring Industry has in response to the requested toxicity data in FGE.86 submitted additional 
data for three of the five substances [FL-no: 16.091, 16.093 and 16.094]. The following information 
has been submitted: 
Ames test and acute oral toxicity test have been submitted by Industry on [FL-no: 16.093]. The 
Industry suggests that these data also can support the evaluation of [FL-no: 16.091 and 16.094]. These 
studies do not fulfil the suggested minimum requirement to provide an adequate NOAEL for 
flavourings in the Procedure, which is considered to be a 90-day study. The minimum requirement has 
not been met by the new toxicity data submitted by Industry for the substances in FGE.86 therefore 
additional toxicity data is still requested. 
Further has Industry submitted Ames test and a 28 day study on substance [FL-no: 16.095] (evaluated 
in FGE.94 (EFSA, 2010i)) to support the evaluation of [FL-no: 16.091, 16.093 and 16.094]. The Panel 
did not consider [FL-no: 16.095] sufficiently structurally related to be used as supporting substance for 
this FGE.  
In addition to the five substances [FL-no: 11.014, 14.003, 16.091, 16.093 and 16.094] for which the 
Panel did not agree that appropriate studies are available for deriving NOAELs, butyramide [FL-no: 
16.049] cannot be evaluated through the Procedure due to concern with respect to 
genotoxicity/carcinogenicity. For N-isopentylidene isopentylamine [FL-no: 11.017] the Panel 
concluded that this substance can be metabolised to innocuous products and accordingly evaluated 
along the A-side of the Procedure (while the JECFA evaluated [FL-no: 11.017] along the B-side). Like 
the JECFA the Panel concluded that [FL-no: 11.017] is of no safety concern at estimated level of 
intake, based on the MSDI approach. So, the Panel did not agree with the application of the Procedure 
as performed by the JECFA for 7 of the 34 substances. 
For 22 substances evaluated by the JECFA through the Procedure use levels have been provided by 
the Industry [FL-no: 11.002, 11.004, 11.005, 11.007, 11.014, 11.015, 11.016, 11.018, 11.020, 11.021, 
11.023, 11.025, 11.026, 14.080, 14.133, 14.141, 16.049, 16.052, 16.091, 16.092, 16.093 and 16.094]. 
The mTAMDI figures calculated for the substances in structural class I are 340 microgram/person/day, 
except for [FL-no: 16.092], for which the mTAMDI is 15000 microgram/person/day, exceeding the 
threshold of 1800 microgram/person/day for structural class I. The mTAMDI figures for the structural 
class II substances range from 200 to 340 microgram/person/day, except for [FL-no: 14.141] for which 
the figure is 600 microgram/person/day, exceeding the threshold of 540 microgram/person/day for 
structural class II. For the substances [FL-no: 11.014, 16.052, 16.091, 16.093 and 16.094] in structural 
class III the figures range from 200 to 1900 microgram/person/day, exceeding the threshold of concern 
of 90 microgram/person/day for structural class III. Thus, for seven substances [FL-no: 11.014, 
14.141, 16.052, 16.091, 16.092, 16.093 and 16.094] the intakes, estimated on the basis of the 
mTAMDI approach, exceed the threshold for their structural classes. Therefore more reliable exposure 
data are required. On the basis of such additional data, these flavouring substances should be 
considered using the Procedure. Subsequently, additional data might become necessary. 
For the remaining 12 substances [FL-no: 11.001, 11.003, 11.006, 11.009, 11.017, 14.003, 14.010, 
14.064, 14.167, 16.006, 16.013 and 16.053] use levels are needed to calculate the mTAMDIs in order 
to identify those flavouring substances that need more refined exposure assessment and to finalise the 
evaluation. 
In order to determine whether the conclusion for the 34 JECFA evaluated substances can be applied to 
the materials of commerce, it is necessary to consider the available specifications. Specifications 
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including complete purity criteria and identity are available for 33 of the 34 JECFA evaluated 
substances. For one substance [FL-no: 16.013] information on the stereoisomeric composition is 
lacking.  
Thus, for one substance [FL-no: 16.013] the Panel has reservation (information on stereoisomeric 
composition is requested).  
For seven of the 34 evaluated substances the Panel did not agree with the JECFA application of the 
Procedure and additional toxicity data are required for five of the seven substances [FL-no: 11.014, 
14.003, 16.091, 16.093 and 16.094]. One substance cannot be evaluated through the Procedure due to 
concern with respect to genotoxicity/carcinogenicity [FL-no: 16.049] and one substance [FL-no: 
11.017] is evaluated along the A-side, while the JECFA evaluated it along the B-side. 
Overall, for 27 of the 34 JECFA evaluated aliphatic and aromatic amines and amides [FL-no: 11.001, 
11.002, 11.003, 11.004, 11.005, 11.006, 11.007, 11.009, 11.015, 11.016, 11.017, 11.018, 11.020, 
11.021, 11.023, 11.025, 11.026, 14.010, 14.064, 14.080, 14.133, 14.141, 14.167, 16.006, 16.052, 
16.053 and 16.092] the Panel agreed with the JECFA conclusion “no safety concern at estimated 
levels of intake as flavouring substances” based on the MSDI approach. 
 
 
© European Food Safety Authority, 2011  
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BACKGROUND 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996a) lays down a 
Procedure for the establishment of a list of flavouring substances, the use of which will be authorised 
to the exclusion of all other substances in the EU. In application of that Regulation, a Register of 
flavouring substances used in or on foodstuffs in the Member States was adopted by Commission 
Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 2009/163/EC (EC, 
2009a). Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are 
divided into 34 chemical groups. Substances within a group should have some metabolic and 
biological behaviour in common. 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a), which is broadly based on the 
Opinion of the Scientific Committee on Food (SCF, 1999a).  
Commission Regulation (EC) No 1565/2000 lays down that substances that are contained in the 
Register and will be classified in the future by the Joint FAO/WHO Expert Committee on Food 
Additives (the JECFA) so as to present no safety concern at current levels of intake will be considered 
by the European Food Safety Authority (EFSA), who may then decide that no further evaluation is 
necessary. 
In the period 2000 – 2008, during its 55th, 57th, 59th, 61st, 63rd, 65th, 68th and 69th meetings, the JECFA 
evaluated about 1000 substances, which are in the EU Register. 
TERMS OF REFERENCE 
EFSA is requested to consider the JECFA evaluations of flavouring substances assessed since 2000, 
and to decide whether no further evaluation is necessary, as laid down in Commission Regulation (EC) 
No 1565/2000 (EC, 2000a). These flavouring substances are listed in the Register which was adopted 
by Commission Decision (EC) No 1999/217 EC (EC, 1999a) and its consecutive amendments. 
In addition, in letter of 19 May 2009 the Commission requested EFSA to carry out a re-evaluation of 
flavouring substances [FL-no: 16.091, 16.093 and 16.094] in accordance with Commission Regulation 
(EC) No 1565/2000: 
“The European Commission requests the European Food Safety Authority to carry out a risk 
assessment on 2,4-Decadienamide, N-(2-methylpropyl)-,  (2E,4E)- ([FL-no: 16.091]), N-Cyclopropyl 
(2E,6Z)-nonadienamide ([FL-no: 16.093]) and N-Ethyl (2E,6Z)-nonadienamide ([FL-no: 16.094]) in 
accordance with Commission Regulation (EC) No 1565/2000, if possible by the end of the evaluation 
programme, if not within nine month from finalisation of that programme”.   
The deadline of the Terms of Reference was negotiated to 31 December 2010. 
ASSESSMENT 
The approach used by EFSA for safety evaluation of flavouring substances is referred to in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a), hereafter named the “EFSA Procedure”. 
This Procedure is based on the Opinion of the Scientific Committee on Food (SCF, 1999a), which has 
been derived from the evaluation Procedure developed by the Joint FAO/WHO Expert Committee on 
Food Additives (JECFA, 1995; JECFA, 1996a; JECFA, 1997a; JECFA, 1999b), hereafter named the 
“JECFA Procedure”. The Panel on Food Contact Materials, Enzymes, Flavourings and Processing 
Aids (the Panel) compares the JECFA evaluation of structurally related substances with the result of a 
corresponding EFSA evaluation, focussing on specifications, intake estimations and toxicity data, 
especially genotoxicity data. The evaluations by EFSA will conclude whether the flavouring 
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substances are of no safety concern at their estimated levels of intake, whether additional data are 
required or whether certain substances should not be put through the EFSA Procedure. 
The following issues are of special importance. 
Intake 
In its evaluation, the Panel as a default uses the “Maximised Survey-derived Daily Intake” (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe.  
In its evaluation, the JECFA includes intake estimates based on the MSDI approach derived from both 
European and USA production figures. The highest of the two MSDI figures is used in the evaluation 
by the JECFA. It is noted that in several cases, only the MSDI figures from the USA were available, 
meaning that certain flavouring substances have been evaluated by the JECFA only on the basis of 
these figures. For Register substances for which this is the case the Panel will need EU production 
figures in order to finalise the evaluation. 
When the Panel examined the information provided by the European Flavour Industry on the use 
levels in various foods, it appeared obvious that the MSDI approach in a number of cases would 
grossly underestimate the intake by regular consumers of products flavoured at the use level reported 
by the Industry, especially in those cases where the annual production values were reported to be 
small. In consequence, the Panel had reservations about the data on use and use levels provided and 
the intake estimates obtained by the MSDI approach. It is noted that the JECFA, at its 65th meeting 
considered ”how to improve the identification and assessment of flavouring agents, for which the 
MSDI estimates may be substantially lower than the dietary exposures that would be estimated from 
the anticipated average use levels in foods” (JECFA, 2006c). 
In the absence of more accurate information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a “modified Theoretical Added Maximum Daily Intake” 
(mTAMDI) approach based on the normal use levels reported by Industry. 
As information on use levels for the flavouring substances has not been requested by the JECFA or 
has not otherwise been provided to the Panel, it is not possible to estimate the daily intakes using the 
mTAMDI approach for the substances evaluated by the JECFA. The Panel will need information on 
use levels in order to finalise the evaluation. 
Threshold of 1.5 Microgram/Person/Day (Step B5) Used by the JECFA 
The JECFA uses the threshold of concern of 1.5 microgram/person/day as part of the evaluation 
Procedure: 
“The Committee noted that this value was based on a risk analysis of known carcinogens which 
involved several conservative assumptions. The use of this value was supported by additional 
information on developmental toxicity, neurotoxicity and immunotoxicity. In the judgement of the 
Committee, flavouring substances for which insufficient data are available for them to be evaluated 
using earlier steps in the Procedure, but for which the intake would not exceed 1.5 microgram per 
person per day would not be expected to present a safety concern. The Committee recommended that 
the Procedure for the Safety Evaluation of Flavouring Agents used at the forty-sixth meeting be 
amended to include the last step on the right-hand side of the original procedure (“Do the condition of 
use result in an intake greater than 1.5 microgram per day?”)” (JECFA, 1999b).  
In line with the Opinion expressed by the Scientific Committee on Food (SCF, 1999), the Panel does 
not make use of this threshold of 1.5 microgram per person per day. 
Genotoxicity 
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As reflected in the Opinion of SCF (SCF, 1999a), the Panel has in its evaluation focussed on a 
possible genotoxic potential of the flavouring substances or of structurally related substances. 
Generally, substances for which the Panel has concluded that there is an indication of genotoxic 
potential in vitro, will not be evaluated using the EFSA Procedure until further genotoxicity data are 
provided. Substances for which a genotoxic potential in vivo has been concluded, will not be evaluated 
through the Procedure. 
Specifications 
Regarding specifications, the evaluation by the Panel could lead to a different opinion than that of 
JECFA, since the Panel requests information on e.g. isomerism. 
Structural Relationship  
In the consideration of the JECFA evaluated substances, the Panel will examine the structural 
relationship and metabolism features of the substances within the flavouring group and compare this 
with the corresponding FGE. 
HISTORY OF THE EVALUATION OF THE SUBSTANCES IN THE PRESENT FGE 
In FGE.86, which considered 35 aliphatic and aromatic amines and amides, the Panel concluded that 
for five substances no applicable NOAEL was available for the substance itself or for a structurally 
related substance and accordingly further data are required. 
FGE Opinion adopted 
by EFSA 
Link No. of candidate 
substances 
86 22 May 2008 http://www.efsa.europa.eu/EFSA/efsa_locale-
1178620753812_1211902197654.htm 
35 
86Rev1 25 November 2010  34 
 
The present Revision of Flavouring Group Evaluation 86, Revision 1 (FGE.86Rev1) concerns the re-
consideration of three JECFA-evaluated substances considered in FGE.86. 
Additional data (Ames test, acute oral toxicity test) have been submitted by Industry on [FL-no: 
16.093]. The Industry suggests that these data also can support the evaluation of [FL-no: 16.091 and 
16.094]. 
Further has Industry submitted additional data (Ames test and a 28 day study) on substance [FL-no: 
16.095] (evaluated in FGE.94 (EFSA, 2010i)) to support the evaluation of [FL-no: 16.091, 16.093 and 
16.094].  
Industry has also submitted additional information needed on stereoisomeric composition [FL-no: 
16.013], composition of mixture [FL-no: 11.017], specifications (data on solubility [FL-no: 14.064 
and 14.168]), missing ID-tests [FL-no: 11.017, 14.168 and 16.094] and EU production figures [FL-no: 
11.006 and 16.053]. 
[FL-no: 14.168], which contains an alpha,beta-unsaturated ketone structure has been withdrawn from 
this consideration and transferred to FGE.223 for evaluation with respect to genotoxic potential. 
After publication of FGE.86, the JECFA has re-evaluated flavouring substances for which estimated 
intake was originally based on anticipated poundage data (JECFA, 2009c), but for which new tonnage 
data were submitted to the JECFA by Industry. These new tonnage figures are included in the present 
FGE for [FL-no: 11.002, 11.004, 11.005, 11.007, 11.014, 11.015, 11.016, 11.017, 11.018, 11.020, 
11.021, 11.023, 11.025, 11.026, 14.080, 14.133, 14.141, 16.049 and 16.052. 
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Furthermore in FGE.86 two substances [FL-no: 11.006  and 16.053] could not be evaluated using the 
Procedure, as no EU production figures were available. In February 2010, the Industry provided EU 
production figures for these two substances together with similar data on approximately 100 other 
substances from 27 different FGEs. In order to avoid unnecessary delay, these substances were 
evaluated in FGE.96 (EFSA, 2010aj). The outcome of the evaluations have also been included in the 
current revision of FGE.86. 
1. Presentation of the Substances in the JECFA Flavouring Group 
1.1. Description 
1.1.1. JECFA Status 
The JECFA has evaluated a group of 37 flavouring substances consisting of aliphatic and aromatic 
amines and amides at the 65th meeting (JECFA, 2006d).  
1.1.2. EFSA Considerations 
Two of the 37 flavouring substances evaluated by the JECFA in the group named “aliphatic and 
aromatic amines and amides” are not in the Register (1-amino-2-propanol and acetamide; JECFA-no: 
1591 and 1592, respectively). A third substance evaluated by the JECFA contains an alpha,beta-
unsaturated ketone moiety and has been considered with respect to genotoxicity in FGE.223, 
corresponding to subgroup 5.1 of FGE.19 (EFSA, 2008b), for which a final conclusion regarding its 
genotoxic properties could not be reached and additional data were requested. This consideration 
therefore only deals with 34 flavouring substances. 
The Panel concluded that no corresponding FGE is available. 
1.2. Isomers 
1.2.1. JECFA Status 
The following six substances [FL-no: 11.005, 11.014, 11.020, 14.133, 16.013 and 16.092] in the group 
of JECFA evaluated aliphatic and aromatic amines and amides have one or more chiral centres. Four 
substances [FL-no: 14.003, 16.091, 16.093 and 16.094] can exist as geometrical isomers. 
1.2.2. EFSA Considerations 
In FGE.86, information is lacking about stereoisomerism for one substance [FL-no: 16.013]. After 
publication of FGE.86, Industry has informed that it is a mixture of diastereoisomers (EFFA, 2010a). 
However, information on the ratios of the diastereoisomers is needed. See Table 1.  
1.3. Specifications 
1.3.1. JECFA Status 
The JECFA specifications are available for all 34 substances (JECFA, 2005d). See Table 1. 
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1.3.2. EFSA Considerations 
The available specifications are considered adequate for 33 substances. For one substance [FL-no: 
16.013] additional information on the stereoisomeric mixture is needed (See Section 1.2).  
2. Intake Estimations 
2.1. JECFA Status 
For all 34 substances evaluated through the JECFA Procedure intake data are available for the EU. 
(See Table 3.1). 
After publication of FGE.86, the JECFA has re-evaluated flavouring substances for which estimated 
intake was originally based on anticipated poundage data (JECFA, 2009c), but for which new tonnage 
(production) data were submitted to the JECFA by Industry. These new tonnage figures are included 
in the present FGE for [FL-no: 11.002, 11.004, 11.005, 11.007, 11.014, 11.015, 11.016, 11.017, 
11.018, 11.020, 11.021, 11.023, 11.025, 11.026, 14.080, 14.133, 14.141, 16.049 and 16.052. 
2.2. EFSA Considerations 
For seven substances [FL-no: 11.006, 14.167, 16.053, 16.091, 16.092, 16.093 and 16.094] the Industry 
has submitted production figure for EU to EFSA (EFFA, 2004ao; Flavour Industry, 2004e; Flavour 
Industry, 2004f). These data have been used in this consideration (see Table 2.2.2 and 3.1). 
New tonnage (production) figures are included in the present FGE for [FL-no: 11.002, 11.004, 11.005, 
11.007, 11.014, 11.015, 11.016, 11.017, 11.018, 11.020, 11.021, 11.023, 11.025, 11.026, 14.080, 
14.133, 14.141, 16.049 and 16.052 (See Section 2.1). 
For 22 substances [FL-no: 11.002, 11.004, 11.005, 11.007, 11.014, 11.015, 11.016, 11.018, 11.020, 
11.021, 11.023, 11.025, 11.026, 14.080, 14.133, 14.141, 16.049, 16.052, 16.091, 16.092, 16.093 and 
16.094], the Industry has submitted use levels for normal and maximum use (EFFA, 2005c; Flavour 
Industry, 2004f; EFFA, 2007a) (see Table 2.2.1). Based on these normal use levels mTAMDI figures 
can be calculated (see Table 2.2.2), (EFSA, 2004d). 
Table 2.2.1  Normal and Maximum use levels (mg/kg) available for JECFA evaluated substances in FGE.86 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
11.002 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
- 
- 
1 
5 
1 
5 
0,2 
1 
11.004 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
- 
- 
1 
5 
1 
5 
0,2 
1 
11.005 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
- 
- 
1 
5 
1 
5 
0,2 
1 
11.007 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
1 
5 
- 
- 
1 
5 
1 
5 
0,2 
1 
11.014 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
- 
- 
1 
5 
1 
5 
0,2 
1 
11.015 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
- 
- 
1 
5 
1 
5 
0,2 
1 
11.016 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
- 
- 
1 
5 
1 
5 
0,2 
1 
11.018 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
- 
- 
1 
5 
1 
5 
0,2 
1 
11.020 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
- 
- 
1 
5 
1 
5 
0,2 
1 
11.021 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
- 
- 
1 
5 
1 
5 
0,2 
1 
11.023 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
- 
- 
1 
5 
1 
5 
0,2 
1 
11.025 0,4 0,1 0,4 0,4 - 1 0,2 2 0,2 0,2 - - 0,1 0,2 - 1 1 0,2 
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Table 2.2.1  Normal and Maximum use levels (mg/kg) available for JECFA evaluated substances in FGE.86 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
2 0,5 2 2 - 5 1 10 1 1 - - 0,5 1 - 5 5 1 
11.026 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
- 
- 
1 
5 
1 
5 
0,2 
1 
14.080 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
- 
- 
1 
5 
1 
5 
0,2 
1 
14.133 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
- 
- 
1 
5 
1 
5 
0,2 
1 
14.141 4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
- 
- 
1 
5 
1 
5 
0,2 
1 
16.049 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
1 
5 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
- 
- 
1 
5 
1 
5 
0,2 
1 
16.052 0,4 
2 
0,1 
0,5 
0,4 
2 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
1 
5 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
- 
- 
1 
5 
1 
5 
0,2 
1 
16.091 0,02 
1 
0,02 
1 
0,2 
10 
- 
- 
- 
- 
2 
100 
- 
- 
0,2 
10 
0,02 
1 
0,02 
1 
- 
- 
- 
- 
0,02 
1 
- 
- 
2 
100 
2 
100 
0,02 
1 
0,02 
1 
16.092 0,4 
4 
0,4 
4 
0,4 
4 
- 
- 
- 
- 
40 
400 
- 
- 
4 
40 
0,4 
4 
0,4 
4 
- 
- 
- 
- 
0,4 
4 
- 
- 
40 
400 
40 
400 
0,4 
4 
0,4 
4 
16.093 0,05 
0,5 
0,05 
0,5 
0,5 
5 
- 
- 
- 
- 
5 
50 
1 
10 
0,5 
5 
0,05 
0,5 
0,05 
0,5 
- 
- 
- 
- 
0,05 
0,5 
- 
- 
5 
50 
5 
50 
0,05 
0,5 
0,05 
0,5 
16.094 0,05 
0,5 
0,05 
0,5 
0,5 
5 
- 
- 
- 
- 
5 
50 
1 
10 
0,5 
5 
0,05 
0,5 
0,05 
0,5 
- 
- 
- 
- 
0,05 
0,5 
- 
- 
5 
50 
5 
50 
0,05 
0,5 
0,05 
0,5 
 
 
Table 2.2.2  Estimated intakes based on the MSDI approach and the mTAMDI approach 
FL-no EU Register name MSDI – EU 
(μg/capita/day) 
MSDI – USA 
(μg/capita/day) 
mTAMDI 
(μg/person/day) 
Structural 
class 
Threshold of concern 
(µg/person/day) 
11.001 3-Methylbutylamine 24 0.07  Class I 1800 
11.002 Isobutylamine 0.012 0.09 340 Class I 1800 
11.003 Butylamine 89 0.01  Class I 1800 
11.004 Propylamine 0.012 0.02 340 Class I 1800 
11.005 sec-Butylamine 0.012 2 340 Class I 1800 
11.009 Trimethylamine 130 70  Class I 1800 
11.015 Ethylamine 0.012 0.2 340 Class I 1800 
11.016 Hexylamine 0.024 0.007 340 Class I 1800 
11.018 Isopropylamine 0.012 0.02 340 Class I 1800 
11.020 2-Methylbutylamine 0.012 0.02 340 Class I 1800 
11.021 Pentylamine 0.037 0.2 340 Class I 1800 
11.023 Triethylamine 0.073 0.9 340 Class I 1800 
11.025 Trimethylamine oxide 2.3 0.09 340 Class I 1800 
11.026 Tripropylamine 0.012 0.02 340 Class I 1800 
16.092 N,N-Dimethyl menthyl succinamide 61 88 15000 Class I 1800 
11.006 Phenethylamine 0.075 0.05  Class II 540 
11.007 2-(4-Hydroxyphenyl)ethylamine 0.012 0.02 340 Class II 540 
14.010 Piperidine 88 96  Class II 540 
14.064 Pyrrolidine 0.12 2  Class II 540 
14.080 2-Acetyl-1-pyrroline 0.012 0.1 340 Class II 540 
14.133 2-Methylpiperidine 0.012 0.002 340 Class II 540 
14.141 Piperazine 0.012 0.002 600 Class II 540 
14.167 1-Pyrroline 0.012 0.4  Class II 540 
16.049 Butyramide 0.012 0.002 200 Class II 540 
16.013 N-Ethyl-2-isopropyl-5-
methylcyclohexane carboxamide 
0.4 127  Class III 90 
16.053 2-Isopropyl- N,2,3-
trimethylbutanamide 
24 1054  Class III 90 
11.014 N,N-Dimethylphenethylamine 0.012 0.09 340 Class III 90 
11.017 N-Isopentylidene isopentylamine 0.012 0.01  Class III 90 
14.003 Piperine 20 0.07  Class III 90 
16.006 N-Nonanoyl 4-hydroxy-3-
methoxybenzylamide 
6.0 0.07  Class III 90 
16.052 1,6-Hexalactam 0.012 0.002 200 Class III 90 
16.091 Deca-(2E,4E)-dienoic acid isobutyl-
amide 
6.1 83 770 Class III 90 
16.093 N-Cyclopropyl (2E,6Z)-
nonadienamide 
61 40 2000 Class III 90 
16.094 N-Ethyl (2E,6Z)-nonadienamide 61 88 2000 Class III 90 
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3. Genotoxicity Data 
3.1. Genotoxicity Studies – Text Taken4 from the JECFA (JECFA, 2006d) 
In vitro 
No mutagenicity was found in the standard Ames assay when various strains of Salmonella 
typhimurium (TA97a, TA98, TA100, TA102, TA1535, TA1537, TA1538, TA1530, TA1531, TA1532 
and TA1964) were incubated with up to 10000 microgram/plate of ethylamine [FL-no: 11.015], 
isopropylamine [FL-no: 11.018], butylamine [FL-no: 11.003], isobutylamine [FL-no: 11.002], 
pentylamine [FL-no: 11.021], acetamide (No. 1592, not in Register), 2-isopropyl-N,2,3-
trimethylbutyramide [FL-no: 16.053], N-isobutyl (E,E)-2,4-decadienamide [FL-no: 16.091], piperine 
[FL-no: 14.003], piperidine [FL-no: 14.010], pyrrolidine [FL-no: 14.064], trimethylamine [FL-no: 
11.009], triethylamine [FL-no: 11.023] or piperazine [FL-no: 14.141] with or without metabolic 
activation (Green & Savage, 1978; Haworth et al., 1978; Andrews et al., 1980; Florin et al., 1980; 
Haworth et al., 1983; Mortelmans et al., 1986; Zeiger et al., 1987; Karekar et al., 1996; King, 2003). 
In a host-mediated assay in which S. typhimurium strain TA1950, TA1951, TA1952 or TA1964 was 
injected intraperitoneally into mice followed by an intramuscular injection of 800 mg/kg bw of 
piperidine or pyrrolidine, no mutagenicity was observed (Green & Savage, 1978).  
There was no evidence of DNA damage when Escherichia coli 343/591 uvrB-/recA-/lac+ or 
uvrB+/recA+/lac+ was incubated with up to 1080 mM (63793 microgram/ml) of acetamide (No. 1592, 
not in Register) or up to 33.7 mM (2870 microgram/ml) of piperidine [FL-no: 14.010] (Hellmér & 
Bolcsfoldi, 1992a). In the SOS Chromotest with E. coli PQ37, the N-nitroso derivative of tyramine 
[FL-no: 11.007] gave positive results (Ohshima et al., 1989). 
Assays in mammalian cell lines have been performed with tyramine [FL-no: 11.007], acetamide (No. 
1592, not in Register), 2-isopropyl-N,2,3-trimethylbutyramide [FL-no: 16.053], and piperidine [FL-
no: 14.010]. Unscheduled DNA synthesis was not increased when WI-38 human cells were incubated 
with 125 - 2000 microgram/ml of 2-isopropyl-N,2,3-trimethylbutyramide (Skinner, 1978). No single-
strand DNA breaks were reported when 0.03 - 1000 mM (2 - 59068 microgram/ml) of acetamide or 
0.03 - 3 mM (2.6 to 255 microgram/ml) of piperidine were incubated with rat hepatocytes (Sina et al., 
1983). Mixed results have been reported with tyramine and piperidine in the mouse lymphoma 
forward mutation assay: positive results were reported for both compounds when tested at up to 823 
and 688 microgram/ml, respectively, in L5178Y mouse lymphoma cells with and without metabolic 
activation, but only at cytotoxic doses (Wangenheim & Bolcsfoldi, 1988). No mutagenic effects were 
reported when tyramine and 2-isopropyl-N,2,3-trimethylbutyramide were tested at concentrations of 
up to 3500 and 1000 microgram/ml, respectively, in L5178Y mouse lymphoma cells (Kirby et al., 
1978; McGregor et al., 1988c). No mutagenic effects were observed when piperidine was tested at 
concentrations of up to 512 microgram/ml without metabolic activation in L5178Y mouse lymphoma 
cells; however, equivocal results were noted when metabolic activation was added (Garberg et al., 
1988). 
In vivo 
In male and female C57B1/6, male CBA, male CD1 and male BDF1 mice, a single dose of acetamide 
(No. 1592, not in Register) of up to 5000 mg/kg bw did not induce micronuclei in the bone marrow or 
peripheral blood when administered by gavage or intraperitoneal injection (Mirkova, 1996; Morita et 
al., 1997). Micronuclei were found in the bone marrow of female C57B1/6 mice given 3.39 mmol/kg 
bw (approximately 200 mg/kg bw) of acetamide by gavage 30 and 6 h before termination; however, 
no dose-response relation was seen, as only a single dose was used (Chieli et al., 1987).  
                                                     
 
4 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present FGE has been removed. 
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Piperine [FL-no: 14.003] did not induce micronuclei in the bone marrow of male Swiss mice given a 
single dose of 10 or 20 mg/kg bw by gavage (Karekar et al., 1996) or two intraperitoneal doses (at 0 
and 24 h) for a total dose of up to 4 mg/kg bw (Muralidhara & Narasimhamurthy, 1990). 
Male and female 1C3F1 mice were given a single dose of 1000 mg/kg bw of 1,6-hexalactam [FL-no: 
16.052] by gavage, and bone marrow was sampled from groups of 10 animals after 24, 30 and 48 h. 
Colchicine was administered to the mice 1 h before sacrifice. No chromosomal aberrations were seen 
(Adler & Ingwersen, 1989). The Comet assay was used to quantify DNA damage in cells from organs 
of male ddy mice given either acetamide (No. 1592, not in Register) or 1,6-hexalactam [FL-no: 
16.052]. No DNA damage was reported in mice given a single dose of 2000 mg/kg bw 1,6-hexalactam 
by gavage; however, DNA damage was reported in the stomach, colon, lungs and bone marrow of 
male mice given a single intraperitoneal injection of acetamide at 2,000 mg/kg bw (Sasaki et al., 
2000). 
1,6-Hexalactam [FL-no: 16.052] did not induce replicative DNA synthesis in rat or mouse hepatocytes 
after treatment in vivo or in vitro at a dose of 350 or 700 mg/kg bw or 250 or 500 mg/kg bw, 
respectively (Uno et al., 1994; Miyagawa et al., 1995). In the mouse spot test, a single [route not stated 
but assumed to be intraperitoneal] injection of 1,6-hexalactam at a dose of up to 500 mg/kg bw 
significantly increased the frequency of spots over those in controls (Neuhäuser-Klaus & Lehmacher, 
1989); however, statistically significant effects were observed in only one of three or four trials. It has 
been suggested that the colour spots observed were indicative of mitotic recombination and not 
mutation (Fahrig, 1989). Moreover, administration of 700 mg/kg bw in one trial did not significantly 
increase the frequency of spots over that in controls (Neuhäuser-Klaus & Lehmacher, 1989).  
Female Drosophila melanogaster larvae fed up to 20 mmol/l (2263 microgram/ml) of 1,6-hexalactam 
[FL-no: 16.052] showed sex-linked recessive lethal mutations and somatic mutation-mitotic 
recombination, whereas male larvae fed up to 5 mmol/l (566 microgram/ml) did not have sex-linked 
recessive lethal mutations (Vogel, 1989).  
Piperidine [FL-no: 14.010] and pyrrolidine [FL-no: 14.064] were tested for promoting activity in male 
Wistar rats given a single dose of 100 mg/kg bw of the test substance by gavage in dimethyl 
sulphoxide or 1 % Tylose. The number of mitoses in the adrenal cortex was examined 36 h after 
dosing. Only administration of pyrrolidine in dimethyl sulphoxide caused a statistically significant 
increase (approximately two-fold) in the number of mitoses over that in controls (Danz & Urban, 
1979).  
Piperine [FL-no: 14.003] and piperidine [FL-no: 14.010] did not cause mutations in male germ cells, 
as assessed by sperm shape abnormality and tests for dominant lethal mutations in mice and hamsters. 
Mice given piperine at doses of up to 75 mg/kg bw/day by gavage or up to 4 mg/kg bw per day by 
intraperitoneal injection for 5 days showed no sperm shape abnormalities or dominant lethal mutations 
(Muralidhara & Narasimhamurthy, 1990; Karekar et al., 1996; Daware et al., 2000). In another study, 
an oral dose of 400 mg/kg bw/day of piperidine for 40-100 days did not induce sperm shape 
abnormalities in mice or hamsters (Bempong & Scully, 1983).  
Conclusion on genotoxicity 
Negative results were reported in bacterial assays for reverse mutation with 15 aliphatic and aromatic 
amine and amide derivatives: ethylamine, isopropylamine, butylamine, isobutylamine, sec-butylamine, 
pentylamine, acetamide, 2-isopropyl-N,2,3-trimethylbutyramide, N-isobutyl (E,E)-2,4-decadienamide, 
piperine, piperidine, pyrrolidine, trimethylamine, triethylamine and piperazine.  
Two substances, tyramine and piperidine, gave both positive and negative results in the mouse 
lymphoma assay, particularly at cytotoxic concentrations, while nitrosated tyramine gave positive 
results in the SOS Chromotest with E. coli.  
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Piperine and piperidine consistently gave negative results in a variety of studies in vivo, whereas 
acetamide, 1,6-hexalactam and pyrrolidine gave mainly negative results with some positive findings.  
For a summary of in vitro / in vivo genotoxicity data considered by the JECFA, see Table 2.1. 
3.2. EFSA Considerations 
The only valid positive in vivo genotoxicity studies cited by the JECFA are related to acetamide, 
which the JECFA considered inappropriate to be used as a flavouring substance due to its reported 
carcinogenicity in both rats and mice, and consequently it was not evaluated using the Procedure.  
As butyramide [FL-no: 16.049] is structurally related to acetamide the Panel concluded not to evaluate 
butyramide through the Procedure. 
N-nonanoyl 4-hydroxy-3-methoxybenzylamide [FL-no: 16.006] (Nonivamide, pelargonyl 
vanillylamide (PAVA)) is structurally related to capsaicin. Capsaicin has been evaluated by SCF in 
2002 (SCF, 2002h) and concluded to have shown genotoxic effects in vitro and in vivo and 
accordingly deleted from the Register. However, N-nonanoyl 4-hydroxy-3-methoxybenzylamide has 
more recently been evaluated by the UK Committee on Toxicity of Chemicals in Food in 2004 (COT, 
2004) and concluded not to be an in vivo mutagen. The Panel agrees with this conclusion made by 
COT in 2004, based on the negative results of a bone marrow cytogenetic assay (COT, 2002) and an 
in vivo liver unscheduled DNA synthesis assay (Clay, 2003). Accordingly N-nonanoyl 4-hydroxy-3-
methoxybenzylamide [FL-no: 16.006] can be evaluated through the Procedure along the B-side, which 
is also done by the JECFA. 
For 1,6-hexalactam [FL-no: 16.052] the Panel noted an increased frequency of spots in only one of 
three or four trials in the mouse spot tests. In addition, sex-linked recessive lethal mutations and 
somatic mutations were reported in female Drosophila larvae fed 1,6-hexalactam. However, 1,6-
hexalactam did not show carcinogenic effects in male and female mice and rats following daily 
administration for two years of up to 2250 mg/kg bw (mice) or up to 350 mg/kg bw (rats).  
Otherwise, the Panel agreed with the JECFA that the available studies on genotoxicity did not 
preclude the evaluation of the aliphatic and aromatic amines and amides by using the Procedure. 
For N-cyclopropyl (2E,6Z)-nonadienamide [FL-no: 16.093] additional genotoxicity data have been 
submitted by EFFA (Bowles, 2003). The substance was tested in a bacterial reverse mutation test 
using S. typhimurium strains TA98, TA100, TA1535, 1537 and E. Coli strain WP2uvrA with and 
without metabolic activation (see Table 2.2). It was concluded to be negative regarding the induction 
of mutagenicity. 
4. Application of the Procedure 
4.1. Application of the Procedure to 34 Aliphatic and Aromatic Amines and Amides by 
JECFA (JECFA, 2006d) 
After publication of FGE.86, the JECFA has re-evaluated flavouring substances for which estimated 
intake was originally based on anticipated poundage data (JECFA, 2009c). New annual production 
volumes were submitted to the JECFA by the Flavour Industry for [FL-no: 11.002, 11.004, 11.005, 
11.007, 11.014, 11.015, 11.016, 11.017, 11.018, 11.020, 11.021, 11.023, 11.025, 11.026, 14.080, 
14.133, 14.141, 16.049 and 16.052]. The JECFA concluded that there was “no safety concern” for 
these substances. 
No new monograph was prepared, so all text about anticipated poundage in Section 4.1 below should 
not be taken into account. 
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Step 1. 
In applying the Procedure for the safety evaluation to these flavouring substances, the Committee 
assigned 15 substances [FL-no: 11.001, 11.002, 11.003, 11.004, 11.005, 11.009, 11.015, 11.016, 
11.018, 11.020, 11.021, 11.023, 11.025, 11.026 and 16.092] to structural class I, nine  flavouring 
substances [FL-no: 11.006, 11.007, 14.010, 14.064, 14.080, 14.133, 14.141, 14.167, and 16.049] to 
structural class II and the remaining ten flavouring substances [FL-no: 11.014, 11.017, 14.003, 16.006, 
16.013, 16.052, 16.053, 16.091, 16.093 and 16.094] to structural class III.  
Step 2. 
Twenty-four  flavouring substances in this group, namely all those in structural classes I and II [FL-
no: 11.001, 11.002, 11.003, 11.004, 11.005, 11.006, 11.007, 11.009, 11.015, 11.016, 11.018, 11.020, 
11.021, 11.023, 11.025, 11.026, 14.010, 14.064, 14.080, 14.133, 14.141, 14.167, 16.049 and 16.092] 
are predicted to be metabolised to innocuous products. The evaluation of these substances therefore 
proceeded via the A-side of the Procedure.  
For the ten flavouring substances in structural class III, namely the medium chain saturated and 
unsaturated aliphatic and alicyclic amides [FL-no: 11.017, 14.003, 16.006, 16.013, 16.052, 16.053, 
16.091, 16.093 and 16.094] and N,N-dimethylphenethylamine [FL-no: 11.014], limited metabolic data 
were available, and evaluation of these substances therefore proceeded via the B-side of the Procedure. 
Step A3. 
The estimated daily per capita exposures to all 15 flavouring substances in structural class I are below 
the threshold of concern (1800 microgram/person/day for class I). Three of these 15 substances [FL-
no: 11.001, 11.003 and 11.009] are reported to be currently used as flavouring substances, and, 
according to the Procedure, the current use and exposure levels of these three substances raise no 
safety concern. The other 12 substances [FL-no: 11.002, 11.004, 11.005, 11.015, 11.016, 11.018, 
11.020, 11.021, 11.023, 11.025, 11.026 and 16.092] are proposed for use as flavouring substances. 
Although, according to the Procedure, the use of these 12 substances raises no safety concern at the 
exposure estimated from anticipated volumes of production, less uncertain estimates are needed. The 
estimated daily per capita exposure to all nine flavouring substances in structural class II is below the 
threshold of concern (540 microgram/day). Three of these nine substances [FL-no: 11.006, 14.010 and 
14.064] are reported to be used as flavouring substances, and, according to the Procedure, their use 
raises no safety concern at current estimated level of exposure. The other six substances [FL-no: 
11.007, 14.080, 14.133, 14.141, 14.167 and 16.049] are proposed for use as flavouring substances. 
Although, according to the Procedure, use of these six substances raises no safety concern at the 
exposure levels estimated from anticipated volumes of production, less uncertain exposure estimates 
are needed.  
Step B3. 
The estimated per capita exposures to eight of the flavouring substances in structural class III [FL-no: 
11.014, 11.017, 14.003, 16.006, 16.052, 16.091, 16.093 and 16.094] are below the threshold of 
concern (90 microgram/person/day). One of these substances [FL-no: 14.003] is reported to be used as 
a flavouring substance in Europe and the USA, one [FL-no: 16.006] is reported to be used in Europe 
and to be proposed for use in the USA, and six [FL-no: 11.014, 11.017, 16.052, 16.091, 16.093 and 
16.094] are proposed for use in both regions. For those eight substances proposed for use in flavours 
in one or more region [FL-no: 11.014, 11.017, 14.003, 16.006, 16.052, 16.091, 16.093 and 16.094], 
less uncertain exposure estimates are needed. In accordance with the Procedure, evaluation of these 
eight flavouring substances proceeded to Step B4.  
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The per capita exposures in the USA of the two remaining flavouring substances in structural class III, 
2-isopropyl-N-2,3-trimethylbutyramide ([FL-no: 16.053]; exposure, 1054 microgram/day) and N-
ethyl-2-isopropyl-5-methylcyclohexane carboxamide ([FL-no: 16.013]; exposure, 127 
microgram/day), exceed the threshold of concern for their structural class (90 microgram/person/day). 
In accordance with the Procedure, data must be available on these substances or closely related 
substances for a safety evaluation. For [FL-no: 16.053], which is proposed for use as a flavouring 
substance, a less uncertain exposure estimate is needed. 
Step B4. 
The No Observed Effect Level (NOEL) of 750 mg/kg bw/day for 1,6-hexalactam [FL-no: 16.052] in a 
90-day feeding study in rats (NTP, 1982a) is at least 2.5 x 1010 times higher than the estimated 
exposure from its proposed use as a flavouring substance in Europe (0.00002 microgram/kg bw/day) 
and in the USA (0.00003 microgram/kg bw/day).  
The NOEL of 572 mg/kg bw/day for the structurally related substance, N-isobutyl-2,6,8-
decatrienamide [FL-no: 16.121] (Moore, 2002), is applicable to N-ethyl (2E,6Z)-nonadienamide [FL-
no: 16.094], N-cyclopropyl (2E,6Z)-nonadienamide [FL-no: 16.093] and deca-(2E,4E)-dienoic acid 
isobutylamide [FL-no: 16.091], as they follow similar pathways of metabolism. This NOEL is 600000 
times the estimated exposure to N-ethyl (2E,6Z)-nonadienamide [FL-no: 16.094] from its proposed 
use as a flavouring substance in the USA (1 microgram/kg bw/day) and is more than 800000 times the 
estimated exposure to N-cyclopropyl (2E,6Z)-nonadienamide [FL-no: 16.093] from its proposed use 
as flavouring substance in the USA (0.7 microgram/kg bw/day) and at least 600000 times the 
estimated exposure to deca-(2E,4E)-dienoic acid isobutylamide [FL-no: 16.091] from its proposed use 
as flavouring substance in Europe and in the USA (both 1 microgram/kg bw/day).  
The NOEL of 8.4 mg/kg bw/day for N-nonanoyl 4-hydroxy-3-methoxybenzylamide [FL-no: 16.006] 
(Posternak et al., 1969) is more than 70000 times the estimated exposure from its proposed use as a 
flavouring substance in Europe (0.1 microgram/kg bw/day) and 8.4 x 106 times that in the USA (0.001 
microgram/kg bw/day). 
The NOEL of 20 mg/kg bw/day for piperine [FL-no: 14.003] (Bhat & Chandrasekhara, 1986b) is 
50000 times the estimated exposure to piperine from its reported use as a flavouring substance in 
Europe (0.4 microgram/kg bw/day) and 2 x 107 times that in the USA (0.001 microgram/kg bw/day).  
The NOEL of 115 mg/kg bw/day for the structurally related substance sec-butylamine [FL-no: 11.005] 
(Gage, 1970) is applicable to N-isopentylidene isopentylamine [FL-no: 11.017] and is at least 5.75 x 
108  times the estimated intake to N-isopentylidene isopentylamine from its proposed use as flavouring 
substance in Europe (0.0001 microgram/kg bw/day) and in the USA (0.0002 microgram/kg bw/day). 
The NOEL of 247 ppm in a study in rats treated by inhalation (equivalent to an oral dose of 157 mg/kg 
bw/day) for the structurally related substance triethylamine [FL-no: 11.023] is applicable to N,N-
dimethylphenethylamine [FL-no: 11.014] and is at least 1 x 108 times the estimated exposure to N,N-
dimethylphenethylamine from its proposed use as flavouring substance in Europe (0.001 
microgram/kg bw/day) (Lynch et al., 1990; JECFA, 2006b). 
Consideration of flavour substances with high exposure, evaluated via the B-side of the Procedure 
In accordance with the Procedure, more data on toxicity were considered to evaluate the safety of 2-
isopropyl-N-2,3-trimethylbutyramide [FL-no: 16.053] and N-ethyl-2-isopropyl-5-methylcyclohexane 
carboxamide [FL-no: 16.013], as the estimated exposure levels from proposed use [FL-no: 16.053] 
and reported use [FL-no: 16.013] as flavouring substances were determined to exceed the threshold of 
concern for structural class III (90 microgram per person per day). 
The results of three studies in Sprague-Dawley (CD®) rats treated by gavage were available on 2-
isopropyl-N-2,3-trimethylbutanamide [FL-no: 16.053]: a 14-day study in groups of six rats of each sex 
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at a dose of 0, 5, 25 or 50 mg/kg bw in corn oil twice daily (Nixon & Alden, 1978); a 14-week study 
in groups of 30 rats of each sex at a dose of 0, 10, 50 or 100 mg/kg bw in corn oil once daily (Pence, 
1980a); and a 14-week study in groups of 30 rats of each sex at a dose of 0, 1, 2, 5, 10 or 50 mg/kg bw 
in corn oil once daily (Cheng, 1982). The studies showed treatment-related hepatic and renal toxicity 
at doses of 10 mg/kg bw and higher. The NOEL was 5 mg/kg bw/day, on the basis of 
histopathological lesions in the kidneys of male rats in the 14-week study (Cheng, 1982). A study of 
reproductive and teratogenic toxicity in rats at a dose of 0, 10, 50 or 100 mg/kg bw showed no 
reproductive effects or fetal abnormalities (Pence, 1980b). The NOEL of 5 mg/kg bw/day is 280 times 
the estimated daily exposure to 2-isopropyl-N-2,3-trimethylbutyramide [FL-no: 16.053] when used as 
a flavouring substance in the USA (18 microgram/kg bw/day). 
Two studies were conducted on N-ethyl-2-isopropyl-5-methylcyclohexane carboxamide [FL-no: 
16.013] in rats treated by gavage: a 28-day study in groups of six Crj:CD(SD) rats of each sex at a 
dose of 0, 8, 40, 200 or 1000 mg/kg bw/day (Miyata, 1995) and a 22-week study in groups of 15 
Sprague-Dawley (CFY) rats of each sex at a dose of 0, 100, 300 or 725 mg/kg bw/day. Mild toxicity 
in the liver and kidneys was observed at doses of 40 mg/kg bw and above. Two further studies were 
conducted in beagle dogs given gelatine capsules: a 28-day study in groups of one male and one 
female given a dose of 0, 600, 1000 or 1500 mg/kg bw/day and a 52-week study in groups of three 
animals of each sex given a dose of 0, 100, 300 or 1000 mg/kg bw/day (James, 1974). These studies 
showed mild toxic effects in the liver at all doses. The NOEL of 8 mg/kg bw/day in these studies is 
1000000 times the estimated daily exposure to N-ethyl-2-isopropyl-5-methylcyclohexanecarboxamide 
when used as a flavouring substance in Europe (0.008 microgram/kg bw/day) and 4000 times that in 
the USA (2 microgram/kg bw/day). 
The additional toxicity data indicate that 2-isopropyl-N-2,3-trimethylbutyramide [FL-no: 16.053] and 
N-ethyl-2-isopropyl-5-methylcyclohexane carboxamide [FL-no: 16.013] would not be expected to 
raise safety concerns at their estimated levels of exposure when used as flavouring substances. For one 
of these substances [FL-no: 16.053], however, less uncertain exposure estimates are needed, as the 
existing estimate was based on anticipated poundage. 
In conclusion, the JECFA evaluated all 34 substances as to be of no safety concern at the estimated 
levels of intake as flavouring substances based on the MSDI approach. 
The evaluations of the 34  aliphatic and aromatic amines and amides are summarised in Table 3.1: 
Summary of Safety Evaluation of 34 Aliphatic and Aromatic Amines and Amides (JECFA, 2006d). 
4.2. EFSA Considerations 
After the publication of FGE.86 Industry has submitted additional data (toxicity data and mutagenicity 
data) on substance [FL-no: 16.095] (evaluated in FGE.94 (EFSA, 2010i)) to support the evaluation of 
[FL-no: 16.091, 16.093 and 16.094]. However, for the present evaluation the Panel consider the 
substance [FL no: 16.095] not to be sufficiently structurally related to candidate substances [FL-no: 
16.091, 16.093 and 16.094] owing to the configuration of the amide bond and different characteristics 
of possible hydrolysis products (e.g. cyclopropyl amine and unsaturated carboxylic acid for [FL-no: 
16.093] vs. cyclopropyl carboxylic acid and unsaturated amine for [FL-no: 16.095]; no cyclopropyl 
group in [FL-no: 16.091 and 16.094]. Due to these structural differences, routes of metabolism will 
also be different and also differences in toxicity must be anticipated. 
The Panel agrees with the application of the Procedure as performed by the JECFA for 25 of the 34 
substances in the group. Furthermore, for two more substances [FL-no: 11.006 and 16.053] the EU 
volumen has been provided since the publication of FGE.86. Based on the submitted EU production 
volumes, the Panel could also agree with the application of the Procedure as performed by the JECFA 
for these two substances. Further details can be found in FGE.96 (EFSA, 2010aj). 
Flavouring Group Evaluation 86, Revision 1
 
 
17 EFSA Journal 2011; 9(4):1926 
N-isopentylidene isopentylamine [FL-no: 11.017] is anticipated to be completely hydrolysed to 
isopentylamine and isopentylaldehyde, which are further metabolised to innocuous products. 
Accordingly [FL-no: 11.017] can be anticipated to be metabolised to innocuous products and 
evaluated along the A-side of the Procedure. The JECFA evaluated [FL-no: 11.017] along the B-side. 
As the estimated European per capita intake of 0.0073 microgram is below the treshold of concern for 
structural class III substances of 90 microgram/person/day, the Panel concluded (as did the JECFA) 
that there was no safety concern of the estimated level of intake of [FL-no: 11.017] based on the 
MSDI approach. 
For butyramide [FL-no: 16.049] the Panel, contrary to the JECFA, concluded that this substance 
cannot be evaluated through the Procedure due to structural relationship to acetamide for which the 
Panel has concern with respect to carcinogenicity and a genotoxic mechanism which cannot be 
discounted. 
In contrast to butyramide [FL-no: 16.049] the other amides in the present FGE are amides of 
alkylamines. 
The JECFA derives a No Observed Adverse Effect Level (NOAEL) of 572 mg/kg bw/day for N-
isobutyl-2,6,8-decatrienamide [FL-no: 16.121] from a 28-day feeding study with groups of 10 rats 
given different amounts of an extract of unknown purity from gold root (Halopsis longiper) with an 
estimated concentration of 50 % of N-isobutyl-2,6,8-decatrienamide (Moore, 2002). This study is also 
considered in FGE.303, in which N-isobutyl-2,6,8-decatrienamide [FL-no: 16.121] is the candidate 
substance. The Panel did not agree with the JECFA that the study is appropriate for deriving a 
NOAEL to be used at step B4 of the Procedure for the three substances [FL-no: 16.091, 16.093 and 
16.094], and accordingly additional data are required.  
The JECFA derives a NOAEL of 20 mg/kg bw/day for piperine [FL-no: 14.003] from a 56-day 
feeding study in groups of six rats given different doses of black pepper or oleoresin corresponding to 
up to approximately 20 mg/kg bw/day or 100 mg piperine/kg feed corresponding to up to 
approximately 10 mg/kg bw/day. No histopathology was performed. The Panel did not agree with the 
JECFA that the study is appropriate for deriving a NOAEL to be used at step B4 of the Procedure for 
piperine [FL-no: 14.003], and accordingly additional data are required. 
The JECFA derives a NOAEL of 157 mg/kg bw/day from an inhalation study in groups of 100 rats 
exposed to 25 or 247 ppm triethylamine per day for up to 120 days, estimate to correspond to 25 to 
157 mg/kg bw/day, respectively (Lynch et al., 1990). The Panel did not agree with the JECFA that the 
study is appropriate for deriving a NOAEL to be used at step B4 of the Procedure for N,N-
dimethylphenethylamine [FL-no: 11.014] (JECFA, 2006b) and accordingly additional data are 
required. 
The Panel considered further the possible consequences of nitrosation after ingestion of the secondary 
and tertiary amine and secondary amide candidate substances according to the approach described in 
the Annex to the minutes of the 30th AFC Panel meeting, May 2008 (EFSA, 2008e). From these 
considerations, the Panel concluded that extremely large margins of exposure could be calculated (>> 
109) for nitrosated products possibly formed from amines used as flavouring substances in foods. Such 
large margins of exposure indicate that a risk of carcinogenicity resulting from such possible 
nitrosation products is virtually absent. 
The Panel also noted that this conclusion is not applicable for foods preserved with nitrites, because 
for such foods the conditions for nitrosation, either in the foods themselves or after consumption in the 
stomach, may differ substantially from the worst-case conditions on which the calculations in the 
above mentioned Annex were based.  
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5. Conclusion 
The Panel has considered 34 of 37 substances in the JECFA flavouring group of aliphatic and aromatic 
amines and amides. The Panel concluded that no corresponding FGE is available. 
A further two substances were evaluated by the JECFA in this group, but these are not in the Register 
(1-amino-2-propanol and acetamide; JECFA-no: 1591 and 1592, respectively). A third substance 
evaluated by the JECFA is an alpha,beta-unsaturated ketone [FL-no: 14.168] considered with respect 
to genotoxicity in FGE.223, corresponding to subgroup 5.1 of FGE.19, for which a final conclusion 
regarding its genotoxic properties could not be reached and additional data were requested. This 
consideration therefore only deals with 34 flavouring substances. 
The Panel agreed with the application of the Procedure as performed by the JECFA for 27 of the 34 
substances. The JECFA concluded on five substances [FL-no: 11.014, 14.003, 16.091, 16.093 and 
16.094] at step B4, but the Panel did not agree that appropriate studies are available for deriving 
NOAELs and accordingly the Panel in FGE.86 concluded that additional toxicity data are required for 
these five substances.  
The flavouring Industry has in response to the requested toxicity data in FGE.86 submitted additional 
data for three of the five substances [FL-no: 16.091, 16.093 and 16.094]. The following information 
has been submitted: 
Ames test and acute oral toxicity test have been submitted by Industry on [FL-no: 16.093]. The 
Industry suggests that these data also can support the evaluation of [FL-no: 16.091 and 16.094]. These 
studies do not fulfil the suggested minimum requirement to provide an adequate NOAEL for 
flavourings in the Procedure, which is considered to be a 90-day study. The minimum requirement has 
not been met by the new toxicity data submitted by Industry for the substances in FGE.86 therefore 
additional toxicity data is still requested. 
Further has Industry submitted Ames test and a 28 day study on substance [FL-no: 16.095] (evaluated 
in FGE.94 (EFSA, 2010i)) to support the evaluation of [FL-no: 16.091, 16.093 and 16.094]. The Panel 
did not consider [FL-no: 16.095] sufficiently structurally related to be used as supporting substance for 
this FGE.  
In addition to the five substances [FL-no: 11.014, 14.003, 16.091, 16.093 and 16.094] for which the 
Panel did not agree that appropriate studies are available for deriving NOAELs, butyramide [FL-no: 
16.049] cannot be evaluated through the Procedure due to concern with respect to 
genotoxicity/carcinogenicity. For N-isopentylidene isopentylamine [FL-no: 11.017] the Panel 
concluded that this substance can be metabolised to innocuous products and accordingly evaluated 
along the A-side of the Procedure (while the JECFA evaluated [FL-no: 11.017] along the B-side). Like 
the JECFA the Panel concluded that [FL-no: 11.017] is of no safety concern at estimated level of 
intake, based on the MSDI approach. So, the Panel did not agree with the application of the Procedure 
as performed by the JECFA for 7 of the 34 substances. 
For 22 substances evaluated by the JECFA through the Procedure use levels have been provided by 
the Industry [FL-no: 11.002, 11.004, 11.005, 11.007, 11.014, 11.015, 11.016, 11.018, 11.020, 11.021, 
11.023, 11.025, 11.026, 14.080, 14.133, 14.141, 16.049, 16.052, 16.091, 16.092, 16.093 and 16.094]. 
The mTAMDI figures calculated for the substances in structural class I are 340 microgram/person/day, 
except for [FL-no: 16.092], for which the mTAMDI is 15000 microgram/person/day, exceeding the 
threshold of 1800 microgram/person/day for structural class I. The mTAMDI figures for the structural 
class II substances range from 200 to 340 microgram/person/day, except for [FL-no: 14.141] for which 
the figure is 600 microgram/person/day, exceeding the threshold of 540 microgram/person/day for 
structural class II. For the substances [FL-no: 11.014, 16.052, 16.091, 16.093 and 16.094] in structural 
class III the figures range from 200 to 1900 microgram/person/day, exceeding the threshold of concern 
of 90 microgram/person/day for structural class III. Thus, for seven substances [FL-no: 11.014, 
14.141, 16.052, 16.091, 16.092, 16.093 and 16.094] the intakes, estimated on the basis of the 
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mTAMDI approach, exceed the threshold for their structural classes. Therefore more reliable exposure 
data are required. On the basis of such additional data, these flavouring substances should be 
considered using the Procedure. Subsequently, additional data might become necessary. 
For the remaining 12 substances [FL-no: 11.001, 11.003, 11.006, 11.009, 11.017, 14.003, 14.010, 
14.064, 14.167, 16.006, 16.013 and 16.053] use levels are needed to calculate the mTAMDIs in order 
to identify those flavouring substances that need more refined exposure assessment and to finalise the 
evaluation. 
In order to determine whether the conclusion for the 34 JECFA evaluated substances can be applied to 
the materials of commerce, it is necessary to consider the available specifications. Specifications 
including complete purity criteria and identity are available for 33 of the 34 JECFA evaluated 
substances. For one substance [FL-no: 16.013] information on the stereoisomeric composition is 
lacking.  
Thus, for one substance [FL-no: 16.013] the Panel has reservation (information on stereoisomeric 
composition is requested).  
For seven of the 34 evaluated substances the Panel did not agree with the JECFA application of the 
Procedure and additional toxicity data are required for five of the seven substances [FL-no: 11.014, 
14.003, 16.091, 16.093 and 16.094]. One substance cannot be evaluated through the Procedure due to 
concern with respect to genotoxicity/carcinogenicity [FL-no: 16.049] and one substance [FL-no: 
11.017] is evaluated along the A-side, while the JECFA evaluated it along the B-side. 
Overall, for 27 of the 34 JECFA evaluated aliphatic and aromatic amines and amides [FL-no: 11.001, 
11.002, 11.003, 11.004, 11.005, 11.006, 11.007, 11.009, 11.015, 11.016, 11.017, 11.018, 11.020, 
11.021, 11.023, 11.025, 11.026, 14.010, 14.064, 14.080, 14.133, 14.141, 14.167, 16.006, 16.052, 
16.053 and 16.092] the Panel agreed with the JECFA conclusion “no safety concern at estimated 
levels of intake as flavouring substances” based on the MSDI approach. 
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TABLE 1: SPECIFICATION SUMMARY  
Table 1: Specifications Summary for the JECFA Evaluated Substances in the Present Group (JECFA, 2005d) 
Table 1: Specification Summary of the Substances in the JECFA Flavouring Group of Aliphatic and Aromatic Amines and Amides (JECFA, 2005d) 
FL-no 
JECFA-
no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
EFSA comments 
11.001 
1587 
3-Methylbutylamine 
H2N  
3219 
512 
107-85-7 
Liquid 
C5H13N 
87.16 
Soluble 
Soluble 
95-97 
 
NMR 
98 % 
1.405-1.411 
0.747-0.753 
 
 
11.002 
1583 
Isobutylamine 
NH2  
 
513 
78-81-9 
Liquid 
C4H11N 
73.14 
Soluble 
Soluble 
68 
 
MS 
95 % 
1.391-1.397 
0.731-0.737 
 
 
11.003 
1582 
Butylamine NH2  3130 
524 
109-73-9 
Liquid 
C4H11N 
73.14 
Soluble 
Soluble 
78 
 
NMR 
99 % 
1.398-1.404 
0.732-0.740 
 
 
11.004 
1580 
Propylamine NH2   
601 
107-10-8 
Liquid 
C3H9N 
59.11 
Soluble 
Soluble 
48 
 
MS 
95 % 
1.384-1.390 
0.714-0.720 
 
 
11.005 
1584 
sec-Butylamine NH2
 
 
707 
13952-84-6 
Liquid 
C4H11N 
73.14 
Soluble 
Soluble 
63 
 
MS 
95 % 
1.387-1.393 
0.715-0.721 
 
Racemate. 
11.006 
1589 
Phenethylamine NH2
 
3220 
708 
64-04-0 
Liquid 
C8H11N 
121.18 
Soluble 
Soluble 
194-195 
 
NMR 
95 % 
1.526-1.532 
(25°) 
0.961-0.967 
 
 
11.007 
1590 
2-(4-Hydroxyphenyl)ethylamine H2N
OH
 
 
709 
51-67-2 
Solid 
C8H11NO 
137.18 
Soluble 
Soluble 
 
165 
MS 
95 % 
n.a. 
n.a. 
 
 
11.009 
1610 
Trimethylamine 
N  
3241 
10497 
75-50-3 
Gas 
C3H9N 
59.11 
Soluble 
Soluble 
3-4 
- 
NMR 
98 % 
n.a. 
0.667-0.675 
(4°) 
 
11.014 
1613 
N,N-Dimethylphenethylamine 
N
 
 
 
19342-01-9 
Liquid 
C10H15N 
149.24 
Soluble 
Soluble 
183 
 
MS 
95 % 
1.500-1.506 
0.898-0.904 
 
Register name to be changed 
to (R)-N,N-
Dimethylphenethylamine. 
11.015 
1579 
Ethylamine NH2   
10477 
Gas 
C2H7N 
Soluble 
Soluble 
17 
-81 
n.a. 
0.682-0.686 
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Table 1: Specification Summary of the Substances in the JECFA Flavouring Group of Aliphatic and Aromatic Amines and Amides (JECFA, 2005d) 
FL-no 
JECFA-
no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
EFSA comments 
75-04-7 45.08 MS 
95 % 
(10°) 
11.016 
1588 
Hexylamine H2N   
10478 
111-26-2 
Liquid 
C6H15N 
101.19 
Soluble 
Soluble 
130 
 
MS 
95 % 
1.415-1.421 
0.761-0.767 
 
 
11.017 
1606 
N-Isopentylidene isopentylamine 
N  
3990 
 
35448-31-8 
Liquid 
C10H21N 
155.29 
Insoluble 
Soluble 
145-148 
 
MS 
98 % 
1.422-1.428 
0.768-0.774 
 
 
11.018 
1581 
Isopropylamine NH2
 
 
10480 
75-31-0 
Liquid 
C3H9N 
59.11 
Soluble 
Soluble 
34 
 
MS 
95 % 
1.367-1.373 
0.687-0.693 
 
 
11.020 
1586 
2-Methylbutylamine NH2
 
 
10484 
96-15-1 
Liquid 
C5H13N 
87.16 
Soluble 
Soluble 
96 
 
MS 
95 % 
1.417-1.423 
0.777-0.779 
 
Racemate. 
11.021 
1585 
Pentylamine H2N   
11734 
110-58-7 
Liquid 
C5H13N 
87.16 
Soluble 
Soluble 
103 
 
MS 
95 % 
1.418-1.424 
0.750-0.759 
 
 
11.023 
1611 
Triethylamine 
N  
 
10496 
121-44-8 
Liquid 
C6H15N 
101.19 
Soluble 
Soluble 
88 
 
MS 
95 % 
1.395-1.401 
0.724-0.730 
 
 
11.025 
1614 
Trimethylamine oxide 
N+ O-
 
 
10494 
1184-78-7 
Solid 
C3H9NO 
75.11 
Soluble 
Soluble 
 
213 
MS 
95 % 
n.a. 
n.a. 
 
 
11.026 
1612 
Tripropylamine 
N  
 
10495 
102-69-2 
Liquid 
C9H21N 
143.27 
Soluble 
Soluble 
156 
 
MS 
95 % 
1.411-1.417 
0.754-0.760 
 
 
14.003 
1600 
Piperine 
N
O
O
O 2909 
492 
94-62-2 
Solid 
C17H19O3N 
285.34 
Very slightly soluble 
Soluble 
 
128-130 
NMR 
97 % 
n.a. 
n.a. 
 
CASrn in the Register refers 
to the (E,E)-isomer. Register 
name to be changed to 
(E,E)-piperidine. 
14.010 
1607 
Piperidine 
N
H  
2908 
675 
110-89-4 
Liquid 
C5H11N 
85.15 
soluble 
Soluble 
106 
 
IR 
98 % 
1.450-1.454 
0.858-0.862 
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Table 1: Specification Summary of the Substances in the JECFA Flavouring Group of Aliphatic and Aromatic Amines and Amides (JECFA, 2005d) 
FL-no 
JECFA-
no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
EFSA comments 
14.064 
1609 
Pyrrolidine 
N
H  
3523 
10491 
123-75-1 
Liquid 
C4H9N 
71.12 
Soluble 
Freely soluble 
87-89 
 
IR NMR 
95 % 
1.440-1.446 
0.847-0.853 
 
 
14.080 
1604 
2-Acetyl-1-pyrroline N O
 
 
 
99583-29-6 
Solid 
C6H9NO 
111.14 
Soluble 
Soluble 
 
19 
MS 
95 % 
n.a. 
n.a. 
 
 
14.133 
1608 
2-Methylpiperidine HN
 
 
 
109-05-7 
Liquid 
C6H13N 
99.18 
Soluble 
Soluble 
118 
 
MS 
95 % 
1.442-1.448 
0.838-0.844 
 
Racemate 
14.141 
1615 
Piperazine 
HN NH
 
 
 
110-85-0 
Solid 
C4H10N2 
86.14 
Soluble 
soluble 
 
109 
MS 
95 % 
n.a. 
n.a. 
 
 
14.167 
1603 
1-Pyrroline 
N
 
 
 
5724-81-2 
Liquid 
C4H7N 
69.10 
Soluble 
Soluble 
87-89 
 
NMR 
99 % 
1.440-1.446 
0.849-0.855 
 
 
16.006 
1599 
N-Nonanoyl 4-hydroxy-3-
methoxybenzylamide 
HO
O
H
N
O
2787 
590 
2444-46-4 
Solid 
C17H27O3N 
293.41 
Slightly soluble 
Soluble 
 
124-128 
NMR 
96 % 
n.a. 
n.a. 
 
 
16.013 
1601 
N-Ethyl-2-isopropyl-5-
methylcyclohexane carboxamide O NH
 
3455 
2298 
39711-79-0 
Solid 
C13H25ON 
211.35 
Insoluble 
Soluble 
 
91-93 
NMR 
98 % 
n.a. 
n.a. 
 
Mixture of diastereoisomers 
(EFFA, 2010a). Range 
should be given.  
CASrn in Register does not 
specify stereoisomeric 
composition. 
16.049 
1593 
Butyramide 
NH2
O
 
 
 
541-35-5 
Solid 
C4H9NO 
87.12 
Soluble 
Soluble 
 
115 
NMR MS 
95 % 
n.a. 
n.a. 
 
 
16.052 
1594 
1,6-Hexalactam HN
O
 
 
 
105-60-2 
Solid 
C6H11NO 
113.16 
Soluble 
Soluble 
 
70 
NMR MS 
95 % 
n.a. 
n.a. 
 
 
16.053 
1595 
2-Isopropyl-N,2,3-
trimethylbutanamide 
HN
O
 
3804 
10459 
51115-67-4 
Solid 
C10H21ON 
171.28 
insoluble 
Soluble 
 
56-64 
NMR 
99 % 
n.a. 
n.a. 
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Table 1: Specification Summary of the Substances in the JECFA Flavouring Group of Aliphatic and Aromatic Amines and Amides (JECFA, 2005d) 
FL-no 
JECFA-
no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
EFSA comments 
16.091 
1598 
Deca-(2E,4E)-dienoic acid isobutyl-
amide 
N
H
O
 
 
 
18836-52-7 
Solid 
C14H23NO 
223.36 
Insoluble 
Soluble 
 
82-90 
IR NMR MS 
95 % 
n.a. 
n.a. 
 
 
16.092 
1602 
N,N-Dimethyl menthyl succinamide 
O
O
N
O
 
 
544714-08-
1 
Liquid 
C16H30O2N2 
282.43 
Slightly soluble 
Soluble 
380 
 
IR NMR 
95 % 
1.522-1.530 
0.965-0.975 
 
Register name to be changed 
to (1R,2S,5R) N,N-
Dimethyl menthyl 
succinamide. 
16.093 
1597 
N-Cyclopropyl (2E,6Z)-
nonadienamide 
N
H
O
 
 
 
608514-55-
2 
Solid 
C12H19NO 
193.29 
Sparingly soluble 
Soluble 
 
33-37 
IR NMR 
95 % 
n.a. 
n.a. 
 
 
16.094 
1596 
N-Ethyl (2E,6Z)-nonadienamide 
N
H
O
 
 
 
608514-56-
3 
Liquid 
C11H19NO 
181.28 
Sparingly soluble 
Soluble 
120 ( 0.8 hPa) 
 
IR NMR MS 
96 % 
1.484-1.493 
0.910-0.920 
 
 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 %  ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
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TABLE 2: GENOTOXICITY DATA  
Table 2.1: Genotoxicity Data (in vitro / in vivo) for 34 Aliphatic and Aromatic Amines and Amides (JECFA, 2006d)  
Table 2.1: Summary of Genotoxicity Data of 34 Aliphatic and Aromatic Amines and Amides evaluated by JECFA  
FL-no 
JECFA-
no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration Results Reference 
In vitro 
11.015 
1579 
Ethylamine NH2  Reverse Mutation S. typhimurium TA98, 
TA100, TA1535, 
TA1537 
100 to 10,000 µg/plate Negative1 (Mortelmans et al., 
1986) 
11.018 
1581 
Isopropylamine NH2
 
Reverse Mutation S. typhimurium TA98, 
TA100, TA1535, 
TA1537 
10 to 10,000 µg/plate Negative1 (Zeiger et al., 1987) 
11.003 
1582 
Butylamine NH2  Reverse Mutation S. typhimurium TA98, 
TA100, TA1535, 
TA1537 
3.3 to 3,333 µg/plate Negative1 (Zeiger et al., 1987) 
Reverse Mutation S. typhimurium TA100 3 µmol/plate (219 
µg/plate)2 
Negative1 (Florin et al., 1980) 
11.002 
1583 
Isobutylamine 
NH2  
Reverse Mutation S. typhimurium TA98, 
TA100, TA1535, 
TA1537 
33 to 10,000 µg/plate Negative1 (Mortelmans et al., 
1986) 
11.005 
1584 
sec-Butylamine    NH2
 
Reverse Mutation S. typhimurium TA98, 
TA100, TA1535, 
TA1537 
10 to 3,333 µg/plate Negative1 (Zeiger et al., 1987) 
11.021 
1585 
Pentylamine H2N  Reverse Mutation S. typhimurium TA98, 
TA100, TA1535, 
TA1537 
33 to 3,333 µg/plate Negative1 (Mortelmans et al., 
1986) 
11.007 
1590 
2-(4-Hydroxyphenyl)ethylamine 
 
H2N
OH
 
Forward Mutation Mouse lymphoma 
L5178Y cells 
500 to 3,500 µg/ml Negative (McGregor et al., 1988c) 
Forward Mutation Mouse lymphoma 
L5178Y cells 
0.08, 0.80, 2.0, 4.0 or 
6.0 mM (11, 109, 274, 
548 and 823 µg/ml)3,4 
Positive 5,6 (Wangenheim & 
Bolcsfoldi, 1988) 
Forward Mutation Mouse lymphoma 
L5178Y cells 
0.40, 0.80, 1.60, 2.39 or 
3.20 mM (55, 109, 220, 
327 and 439 µg/ml)3,4 
Positive 6,7 (Wangenheim & 
Bolcsfoldi, 1988) 
1592 Acetamide (not in Register)  Reverse Mutation S. typhimurium TA98, 
TA100, TA1535, 
TA1537 
100 to 10,000 µg/plate Negative1 (Haworth et al., 1983) 
DNA Repair Escherichia coli 343/591 
uvrB-/recA-/lac+ and 
uvrB+/recA+/lac+ 
Up to 1,080 mM 
(63,793 µg/ml)8 
Negative1 (Hellmér & Bolcsfoldi, 
1992a) 
Single Strand DNA Breaks Rat hepatocytes 0.03, 0.3, 3, 10, 30, 100, 
300, or 1,000 mM (2, 
18, 177, 591, 1,772, 
Negative (Sina et al., 1983) 
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Table 2.1: Summary of Genotoxicity Data of 34 Aliphatic and Aromatic Amines and Amides evaluated by JECFA  
FL-no 
JECFA-
no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration Results Reference 
5,907, 17,720, or 59,068 
µg/ml)8 
16.053 
1595 
2-Isopropyl- N,2,3-trimethylbutanamide    
HN
O
 
Reverse Mutation S. typhimurium TA98, 
TA100, TA1535, 
TA1537, TA1538 
200, 1,000, 5,000, 
10,000 or 20,000 
µg/plate 
Negative1 Haworth et al. (1978) 
Forward Mutation Mouse lymphoma 
L5178Y cells 
0.01 to 1,000 µg/ml Negative1 Kirby et al. (1978) 
Unscheduled DNA Synthesis WI-38 cells (human) 125 to 2,000 µg/ml9 Negative1 Skinner (1978) 
16.091 
1598 
Deca-(2E,4E)-dienoic acid isobutylamide 
N
H
O
 
 
Reverse Mutation S. typhimurium TA98, 
TA100, TA102, 
TA1535, TA1537 
5 to 1,500 µg/plate10 Negative5 King (2003) 
Reverse Mutation S. typhimurium TA98, 
TA100, TA102, 
TA1535, TA1537 
5 to 5,000 µg/plate11 Negative7 King (2003) 
14.003 
1600 
Piperine    
N
O
O
O
 
Reverse Mutation S. typhimurium TA97a, 
TA98, TA100, TA102 
0.01, 0.5 or 10 
µmol/plate (3, 143 and 
2,853 µg/plate)12 
Negative1 (Karekar et al., 1996) 
Reverse Mutation (pre-
incubation) 
S. typhimurium TA97a, 
TA98, TA100, TA102 
0.005, 0.05, 0.5 or 5 
µmol/plate (1, 14, 143 
and 1,427 µg/plate)12,13 
Negative1 (Karekar et al., 1996) 
Reverse Mutation S. typhimurium TA98, 
TA100, TA1535, 
TA1537, TA1538 
1,000 µg Negative1 (Andrews et al., 1980) 
14.010 
1607 
Piperidine 
N
H  
 
Reverse Mutation S. typhimurium TA98, 
TA100, TA1535, 
TA1537 
3 µmol/plate (255 
µg/plate)14 
Negative1 (Florin et al., 1980) 
Reverse Mutation S. typhimurium TA1530, 
TA1531, TA1532, 
TA1964 
1 to 5 mg/plate (1,000 to 
5,000 µg/plate)14 
Negative (Green & Savage, 1978) 
Reverse Mutation 
(microsomal assay) 
S. typhimurium TA1530, 
TA1531, TA1532, 
TA1964 
0.15 M (12,772 
µg/ml)14,15 
Negative (Green & Savage, 1978) 
Reverse Mutation (host-
mediated, mice) 
S. typhimurium TA1950, 
TA1951, TA1952, 
TA1964 
800 mg/kg bw16 Negative (Green & Savage, 1978) 
Forward Mutation Mouse lymphoma 
L5178Y cells 
3.03, 4.04, 5.05, 6.06 or 
7.07 mM (258, 344, 
430, 516 and 602 
µg/ml)14 
Positive 5,6 (Wangenheim & 
Bolcsfoldi, 1988) 
Forward Mutation Mouse lymphoma 
L5178Y cells 
4.04, 5.05, 6.06, 7.07 or 
8.08 mM (344, 430, 
516, 602 and 688 
µg/ml)14 
Negative7 (Wangenheim & 
Bolcsfoldi, 1988) 
Forward Mutation Mouse lymphoma 
L5178Y cells 
2.0, 4.01, or 6.01 mM 
(170, 341 and 512 
µg/ml)14 
Negative5 (Garberg et al., 1988) 
Forward Mutation Mouse lymphoma 2.0, 4.01, 6.01 or 8.02  Equivocal (Garberg et al., 1988) 
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Table 2.1: Summary of Genotoxicity Data of 34 Aliphatic and Aromatic Amines and Amides evaluated by JECFA  
FL-no 
JECFA-
no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration Results Reference 
L5178Y cells mM (170, 341, 512 and 
683 µg/ml)14 
7,17
DNA Repair Escherichia coli 343/591 
uvrB-/recA-/lac+ and 
uvrB+/recA+/lac+ 
33.7 mM (2,870 
µg/ml)14,18 
Negative5 (Hellmér & Bolcsfoldi, 
1992a) 
DNA Repair Escherichia coli 343/591 
uvrB-/recA-/lac+ and 
uvrB+/recA+/lac+ 
101 mM (8,600 
µg/ml)14,18 
Negative5 (Hellmér & Bolcsfoldi, 
1992a) 
Single Strand DNA Breaks Rat hepatocytes 0.03, 0.3 or 3 mM (2.6, 
26 and 255 µg/ml)14 
Negative (Sina et al., 1983) 
14.064 
1609 
Pyrrolidine 
 
N
H  
 
Reverse Mutation S .typhimurium TA100 Up to 3 µmol/plate (213 
µg/plate)19 
Negative1 (Florin et al., 1980) 
Reverse Mutation S .typhimurium TA1530, 
TA1531, TA1532, 
TA1964 
1 to 5 mg/plate (1,000 to 
5,000 µg/plate)3 
Negative (Green & Savage, 1978) 
Reverse Mutation 
(microsomal assay) 
S. typhimurium TA1530, 
TA1531, TA1532, 
TA1964 
0.5 M (35,561 µg/ml)19 Negative (Green & Savage, 1978) 
Reverse Mutation (host-
mediated, mice) 
S .typhimurium TA1950, 
TA1951, TA1952, 
TA1964 
800 mg/kg bw16 Negative (Green & Savage, 1978) 
11.009 
1610 
Trimethylamine 
N
 
Reverse Mutation S .typhimurium TA98, 
TA100, TA1535, 
TA1537 
10 to 1,000 µg/plate Negative1 (Mortelmans et al., 
1986) 
11.023 
1611 
Triethylamine 
N
Reverse Mutation S .typhimurium TA98, 
TA100, TA1535, 
TA1537 
10 to 10,000 µg/plate Negative1 (Zeiger et al., 1987) 
14.141 
1615 
Piperazine 
HN NH
 
Reverse Mutation S .typhimurium TA98, 
TA100, TA1535, 
TA1537 
33 to 3,167 µg/plate Negative1 (Haworth et al., 1983) 
In vivo 
1592 Acetamide (not in Register) 
 
 DNA Damage (Comet assay) Male ddy mice 2,000 mg/kg bw20 Positive 21 (Sasaki et al., 2000) 
Micronuclei (bone marrow) C57B1/6 mice 2,500 or 5,000 mg/kg 
bw22 
Negative (Mirkova, 1996) 
Micronuclei (bone marrow) Male CBA mice 5,000 mg/kg bw22 Negative (Mirkova, 1996) 
Micronuclei (bone marrow 
and peripheral blood) 
Male CD1 mice 500 to 5,000 mg/kg bw23 Negative (Morita et al., 1997) 
Micronuclei (bone marrow 
and peripheral blood) 
Male BDF1 mice 1,250 to 5,000 mg/kg 
bw23 
Negative (Morita et al., 1997) 
Micronuclei (bone marrow) Female C57B1/6 mice 3.39 mmol/kg bw  (200 
mg/kg bw)24,25 
Positive (Chieli et al., 1987) 
16.052 
1594 
1,6-Hexalactam 
 
HN
O
 
DNA Damage (Comet assay) Male ddy mice  2,000 mg/kg bw22 Negative (Sasaki et al., 2000) 
Replicative DNA Synthesis Male F344 rats 350 or 700 mg/kg bw26 Negative (Uno et al., 1994) 
Replicative DNA Synthesis Male B6C3F1 mice 250 or 500 mg/kg bw22 Negative (Miyagawa et al., 1995) 
Flavouring Group Evaluation 86, Revision 1
 
 
27 EFSA Journal 2011; 9(4):1926 
Table 2.1: Summary of Genotoxicity Data of 34 Aliphatic and Aromatic Amines and Amides evaluated by JECFA  
FL-no 
JECFA-
no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration Results Reference 
 Mammalian Spot (C57B1xT)F1 mouse 
embryos 
400 or 500 mg/kg bw22 Positive 27 (Fahrig, 1989) 
Mammalian Spot (TxHT)F1 mouse 
embryos 
500 mg/kg bw28 Positive 29 (Neuhäuser-Klaus & 
Lehmacher, 1989) 
Mammalian Spot (TxHT)F1 mouse 
embryos 
700 mg/kg bw28 Negative (Neuhäuser-Klaus & 
Lehmacher, 1989) 
Sex-Linked Recessive Lethals Male Drosophila 
melanogaster larvae 
5.0 mM30 (566 µg/ml)31 Negative (Vogel, 1989) 
Sex-Linked Recessive Lethals Female Drosophila 
melanogaster larvae 
5.0 or 20.0 mM30 (566 
or 2,263 µg/ml)31 
Positive (Vogel, 1989) 
Somatic Mutation/Mitotic 
Recombination 
Female Drosophila 
melanogaster larvae 
2.5, 5.0, 10.0 or 20.0 
mM30 (283, 566, 1,132 
and 2,263 µg/ml)31 
Positive (Vogel, 1989) 
Chromosomal Aberrations 
(bone marrow) 
Male and female 1C3F1 
mice 
1,000 mg/kg bw22 Negative  (Adler & Ingwersen, 
1989) 
14.003 
1600 
Piperine    
 
N
O
O
O
 
 
Micronuclei (bone marrow) Male Swiss mice 10 or 20 mg/kg bw22 Negative (Karekar et al., 1996) 
Micronuclei (bone marrow) Male Swiss mice 1, 2 or 4 mg/kg bw32 Negative (Muralidhara & 
Narasimhamurthy, 
1990) 
Sperm Morphology Male Swiss mice 10 or 50 mg/kg bw/day33 Negative (Karekar et al., 1996) 
Sperm Morphology Male Swiss mice 35, 50 or 75 mg/kg 
bw/day34 
Negative (Daware et al., 2000) 
Sperm Morphology Male Swiss mice 1, 2 or 4 mg/kg bw/day35 Negative (Muralidhara & 
Narasimhamurthy, 
1990) 
Dominant Lethal Mutations Male and Female Swiss 
mice 
10 or 50 mg/kg bw22 Negative (Karekar et al., 1996) 
Dominant Lethal Mutations Male Swiss mice 4 mg/kg bw/day35 Negative (Muralidhara & 
Narasimhamurthy, 
1990) 
14.010 
1607 
Piperidine 
 
N
H  
 
Mitosis in Adrenocortical 
Cells 
Male Wistar rats 100 mg/kg bw in 
DMSO22 
Negative (Danz & Urban, 1979) 
Mitosis in Adrenocortical 
Cells 
Male Wistar rats 100 mg/kg bw in 1% 
Tylose22 
Negative (Danz & Urban, 1979) 
Sperm Morphology Male hybrid mice 400 mg/kg bw/day36 Negative (Bempong & Scully, 
1983) 
Sperm Morphology Male golden Syrian 
hamsters 
400 mg/kg bw/day36 Negative (Bempong & Scully, 
1983) 
14.064 
1609 
Pyrrolidine 
 
N
H  
 
Mitosis in Adrenocortical 
Cells 
Male Wistar rats 100 mg/kg bw in 1% 
Tylose22 
Negative (Danz & Urban, 1979) 
Mitosis in Adrenocortical 
Cells 
Male Wistar rats 100 mg/kg bw in 
DMSO22 
Positive (Danz & Urban, 1979) 
1 With and without S9. 
2 Calculated using the molecular weight of butrylamine (73.14 g/mol). 
3 Calculated using the molecular weight of tyramine (137.18 g/mol). 
4 Actual compound used in this study was tyramine hydrochloride at concentrations of 0.101 to 7.59 mM (18 to 1,318 μg/ml) without metabolic activation, and 0.506 to 4.05 mM (88 to 703 μg/ml) with metabolic activation. 
5 Without metabolic activation. 
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6 Significant increases in mutation frequency were observed only at cytotoxic doses. 
7 With metabolic activation. 
8 Calculated using the molecular weight of acetamide (59.07 g/mol). 
9 Cytotoxic at 2,000 µg/ml. 
10 Toxic and precipitates at 1,500 µg/plate. 
11 Toxic and precipitates at 5,000 µg/plate. 
12 Calculated using the molecular weight of piperine (285.34 g/mol). 
13 Toxic at 5 µmol/plate without metabolic activation. 
14 Calculated using the molecular weight of piperidine (85.15 g/mol). 
15 Highest non-cytotoxic concentration. 
16 Intraperitoneal injection of S. typhimurium strain with intramuscular injection of test material. 
17 Results observed did not meet the criteria for positive or negative classification. 
18 Concentration at which a significant reduction in the number of colonies of each strain was observed; however, the highest concentration of piperidine tested was 1,010 mM. 
19 Calculated using the molecular weight of pyrrolidine (71.12 g/mol). 
20 Administered via a single intraperitoneal injection. 
21 Increase in DNA damage was observed in the stomach, colon, lungs and bone marrow of mice. 
22 Administered via a single gavage dose. 
23 Single, double, or quadruple intraperitoneal injections, separated by 24 hours, were administered. 
24 Administered by gavage at 30 and 6 hours prior to sacrifice. 
25 Calculated using the molecular weight of acetamide (59.07 g/mol). 
26 Administered via a single subcutaneous injection. 
27 Frequency of spots of genetic relevance was significantly increased relative to controls only in 1 out of 3 trials, and only at the highest dose (500 mg/kg bw). 
28 Administered at a single dose (route not specified). 
29 Significant increase in spots of genetic relevance was observed only in 1 out of 4 groups receiving 500 mg/kg body weight. 
30 Administered in the diet. 
31 Calculated using the molecular weight of 1,6-hexalactam (113.16 g/mol). 
32 Intraperitoneal injection in 2 installments at 0 and 24 hours. 
33 Administered via gavage for 5 days. 
34 Administered orally for 5 consecutive days. 
35 Administered intraperitoneally for 5 days, followed by a 35-day maintenance period. 
36 Piperidine was administered orally to mice for 100 days. However, on day 40 and every subsequent 5 days, 3 mice were killed for examination of sperm morphology. 
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Table 2.2: Additional genotoxicity data submitted by the Industry  
FL-no 
JECFA-
no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration Results Reference Comments 
In vitro  
16.093 
1597 
N-Cyclopropyl (2E,6Z)-nonadienamide 
N
H
O
 
Reverse Mutation S.typhimurium TA98, 
TA100, TA1535, 
TA1537 
Up to 5000 µg/plate Negative1 (Bowles, 2003)  
 Reverse Mutation E.coli WP2 uvrA- Up to 5000 µg/plate Negative1 (Bowles, 2003)  
16.095 
1779 
N-3,7-Dimethyl-2,6-octadienyl 
cyclopropylcarboxamide 
N
H
O
 
Reverse Mutation S.typhimurium TA97a, 
TA1535 
Up to 2000 µg/plate Negative (Next Century 
Incorporated, 2004) 
Cytotoxic at different 
concentration with and 
without S9. 
 
 
Reverse Mutation S.typhimurium TA98, 
TA100 
Up to 5000 µg/plate Negative (Next Century 
Incorporated, 2004) 
Reverse Mutation Escherichia coli WP2 
uvrA (328) 
Up to 2000 µg/plate Negative (Next Century 
Incorporated, 2004) 
 1 With and without S9. 
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TABLE 3: SUMMARY OF SAFETY EVALUATIONS 
Table 3.1: Summary of Safety Evaluation of Aliphatic and Aromatic Amines and Amides (JECFA, 2006d) 
Table 3.1: Summary of Safety Evaluation of Aliphatic and Aromatic Amines and Amides (JECFA, 2006d)  
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
 
Class 2) 
Evaluation procedure 
path 3) 
Outcome on the 
named compound  
[4) or 5)] 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
 
EFSA conclusion on the 
material of commerce 
11.001 
1587 
3-Methylbutylamine 
H2N  
24 
0.07 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach. 
11.002 
1583 
Isobutylamine 
NH2  
0.012 
0.09 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach. 
 
11.003 
1582 
Butylamine NH2  89 
0.01 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach. 
11.004 
1580 
Propylamine NH2  0.012 
0.02 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach. 
 
11.005 
1584 
sec-Butylamine NH2
 
0.012 
2 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
Racemate. 
No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach. 
 
11.009 
1610 
Trimethylamine 
N  
130 
70 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach. 
11.015 
1579 
Ethylamine NH2  0.012 
0.2 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach. 
 
11.016 
1588 
Hexylamine H2N  0.024 
0.007 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach. 
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Table 3.1: Summary of Safety Evaluation of Aliphatic and Aromatic Amines and Amides (JECFA, 2006d)  
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
 
Class 2) 
Evaluation procedure 
path 3) 
Outcome on the 
named compound  
[4) or 5)] 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
 
EFSA conclusion on the 
material of commerce 
 
11.018 
1581 
Isopropylamine NH2
 
0.012 
0.02 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach. 
 
11.020 
1586 
2-Methylbutylamine NH2
 
0.012 
0.02 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
Racemate. 
No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach. 
 
11.021 
1585 
Pentylamine H2N  0.037 
0.2 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach. 
 
11.023 
1611 
Triethylamine 
N  
0.073 
0.9 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach. 
 
11.025 
1614 
Trimethylamine oxide 
N+ O-
 
2.3 
0.09 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach. 
 
11.026 
1612 
Tripropylamine 
N  
0.012 
0.02 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach. 
 
16.092 
1602 
N,N-Dimethyl menthyl succinamide 
O
O
N
O  
61 
88 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
Register name to to be 
changed to (1R,2S,5R)- 
N,N-Dimethyl menthyl 
succinamide. 
No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach. 
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Table 3.1: Summary of Safety Evaluation of Aliphatic and Aromatic Amines and Amides (JECFA, 2006d)  
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
 
Class 2) 
Evaluation procedure 
path 3) 
Outcome on the 
named compound  
[4) or 5)] 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
 
EFSA conclusion on the 
material of commerce 
11.006 
1589 
Phenethylamine NH2 0.075 
0.05 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
11.007 
1590 
2-(4-Hydroxyphenyl)ethylamine H2N
OH
 
0.012 
0.02 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach. 
 
14.010 
1607 
Piperidine 
N
H  
88 
96 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach. 
14.064 
1609 
Pyrrolidine 
N
H  
0.12 
2 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach. 
14.080 
1604 
2-Acetyl-1-pyrroline N O
 
0.012 
0.1 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach. 
 
14.133 
1608 
2-Methylpiperidine HN
 
0.012 
0.002 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
Racemate. 
No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach. 
 
14.141 
1615 
Piperazine 
HN NH
 
0.012 
0.002 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach. 
 
14.167 
1603 
1-Pyrroline 
N
 
0.012 
0.4 
Class II 
A3: Intake below threshold 
4) EU MSDI is available 
No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach 
EU MSDI is available 
No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach. 
16.049 
1593 
Butyramide 
NH2
O
 
0.012 
0.002 
Class II 
A3: Intake below threshold 
4) The Panel concluded that 
the substance cannot be 
evaluated through the 
Procedure due to concern 
with respect to 
genotoxicity/carcinogenicit
The Panel concluded that 
the substance cannot be 
evaluated through the 
Procedure due to concern 
with respect to 
genotoxicity/carcinogenicit
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Table 3.1: Summary of Safety Evaluation of Aliphatic and Aromatic Amines and Amides (JECFA, 2006d)  
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
 
Class 2) 
Evaluation procedure 
path 3) 
Outcome on the 
named compound  
[4) or 5)] 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
 
EFSA conclusion on the 
material of commerce 
y y. 
16.013 
1601 
N-Ethyl-2-isopropyl-5-
methylcyclohexane carboxamide O NH
 
0.4 
127 
Class III 
B3: Intake above threshold 
Data must be 
available 5) 
Data were available 
indicate that the 
substance would not 
be expected to raise 
safety concern. 
Additional data indicate 
that the substance would 
not be expected to raise 
safety concerns at its 
estimated level of intake 
when used as flavourings 
Composition of 
stereoisomeric mixture to 
be specified. 
Additional data indicate 
that the substance would 
not be expected to raise 
safety concern at its 
estimated level of intake 
when used as flavourings. 
16.053 
1595 
2-Isopropyl- N,2,3-
trimethylbutanamide 
HN
O
 
24 
1054 
Class III 
B3: Intake above threshold 
Data must be 
available 5) 
Data were available 
indicate that the 
substance would not 
be expected to raise 
safety concern. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. EFSA concluded 
at step B4: Yes, an 
adequate NOAEL could be 
established 
No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach. 
11.014 
1613 
N,N-Dimethylphenethylamine 
N
 
0.012 
0.09 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) Additional toxicity data 
required 
Additional toxicity data 
required. 
Name to be changed to (R)-
N,N-
Dimethylphenethylamine. 
11.017 
1606 
N-Isopentylidene isopentylamine 
N  
0.012 
0.01 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach. 
 
14.003 
1600 
Piperine 
N
O
O
O
 
20 
0.07 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) Additional toxicity data 
required 
CASrn in the Register 
refers to the trans, trans 
isomer 
Register name to be 
changed to (E,E)-
piperidine. 
Additional toxicity data 
required. 
16.006 
1599 
N-Nonanoyl 4-hydroxy-3-
methoxybenzylamide 
HO
O
H
N
O
6.0 
0.07 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach. 
16.052 
1594 
1,6-Hexalactam HN
O
 
0.012 
0.002 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach. 
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Table 3.1: Summary of Safety Evaluation of Aliphatic and Aromatic Amines and Amides (JECFA, 2006d)  
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
 
Class 2) 
Evaluation procedure 
path 3) 
Outcome on the 
named compound  
[4) or 5)] 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
 
EFSA conclusion on the 
material of commerce 
16.091 
1598 
Deca-(2E,4E)-dienoic acid isobutyl-
amide 
N
H
O
 
6.1 
83 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) Additional toxicity data 
required 
Additional toxicity data 
required. 
16.093 
1597 
N-Cyclopropyl (2E,6Z)-
nonadienamide 
N
H
O
 
61 
40 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) Additional toxicity data 
required 
Additional toxicity data 
required. 
16.094 
1596 
N-Ethyl (2E,6Z)-nonadienamide 
N
H
O
 
61 
88 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) Additional toxicity data 
required 
Additional toxicity data 
required. 
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
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ABBREVIATIONS 
BW  Body Weight 
CAS  Chemical Abstract Service 
CEF  Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
CHO  Chinese hamster ovary (cells) 
CoE  Council of Europe 
COT  Committee on Toxicity of Chemicals in Food 
DMSO  Dimethyl Sulphoxide 
DNA  Deoxyribonucleic acid 
EFSA  The European Food Safety Authority 
EPA  United States Environmental Protection Agency  
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
GLP  Good laboratory practice 
ID  Identity 
Ip  Intraperitoneal 
IR  Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
NCE  Normochromatic erythrocyte 
No  Number 
NOAEL No observed adverse effect level 
NOEL  No observed effect level 
NTP  National Toxicology Program 
PCE  Polychromatic erythrocyte 
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SCE  Sister chromatic exchange 
SCF  Scientific Committee on Food 
WHO  World Health Organisation 
